Keywords

• Supply 6-Ethylchenodeoxycholic acid(Obeticholic Acid)
• lowest price 6-Ethylchenodeoxycholic acid(Obeticholic Acid)
• 6-Ethylchenodeoxycholic acid(Obeticholic Acid) manufacturer

Quick Details

• ProName: Supply lowest price 6-Ethylchenodeoxyc...
• CasNo: 459789-99-2
• Application: pharmaceutical use
• DeliveryTime: ship immediately after confirmation
• PackAge: According to your demand
• Port: any port in China
• ProductionCapacity: Metric Ton/Day
• Purity: 99%
• Transportation: as requested
• LimitNum: 0 Metric Ton

Superiority

Supply lowest price 6-Ethylchenodeoxycholic acid(Obeticholic Acid) manufacturer

Obeticholic acid is a semi-synthetic bile acid analogue and acts as a farnesoid-X receptor (FXR) agonist. It is used for the treatment of primary biliary cholangitis. It is also under investigation for the treatment of other liver diseases,primary biliary cirrhosis, bile acid diarrhea and related disorders. Study has shown that it also has potential for treating nonalcoholicsteatohepatitis (NASH), and portal hypertension. Obeticholic acid takes effect through acting s the agonist of the farnesoid X receptor (FXR), which is the regulator of bile and cholesterol metabolism in the liver. 

Obeticholic acid is also called 6-Ethylchenodeoxycholic acid. It is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids, a natural ligand for farnesoid x receptors (FXR). Obeticholic acid was developed by American pharmaceutical company Intercept as the first drug to treat cholestatic liver disease in 20 years, and it is administered on patients that do not respond well to or cannot tolerate the old standard treatment drug ursodeoxycholic acid. Obeticholic acid has also been tested to treat a more common form of fatty liver – non-alcoholic fatty liver disease (NAFLD). Obeticholic acid can also be developed to treat other liver and intestine diseases.

Farnesoid X receptor (FXR) is a nuclear receptor that is activated by bile acid, with chenodeoxycholic acid (CDCA) being a representative natural ligand. 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of FXR (EC₅₀ = 99 nM).Through FXR, it alters gene expression that results in protection against cholestasis as well as liver fibrosis. 6-ECDCA also, through FXR, promotes the differentiation of adipocytes and enhances insulin signaling in mature adipocytes. In ApoE^-/- mice, 6-ECDCA ameliorates vascular calcification secondary to chronic kidney disease without affecting the development of atherosclerosis

Details